Scientists at the University of Pittsburgh have presented a study that explains why the body’s immune system often fails inside tumors and reveals a way to restore its power. The research, published in Immunity, shows that protecting fragile parts of immune cells called telomeres with antioxidants can make them stronger, longer lasting, and better at fighting cancer.
Inside a tumor, life is tough for immune cells. The cancer environment has little oxygen, high acidity, and extreme stress. These conditions force mitochondria, the tiny engines of the cells, to work too hard. As they burn energy, they release harmful molecules called reactive oxygen species, or ROS.
These molecules move toward the cell’s nucleus, where they damage telomeres. Telomeres are like protective caps at the ends of chromosomes, and once they are damaged, the cell begins to weaken. For T cells, which are the body’s frontline soldiers against cancer, this means exhaustion. They stop working properly, allowing the tumor to grow stronger.
The University of Pittsburgh team discovered that they could stop this process. By attaching a special antioxidant directly to telomeres, they blocked the damage caused by ROS. In tests with mice that had aggressive melanoma, the T cells remained strong, the tumors shrank, and the animals lived longer.
“The really exciting part about this research is that by preventing damage to telomeres via a targeted antioxidant, we can rescue T cell function,” explained Dayana Rivadeneira, assistant professor of immunology at the University of Pittsburgh and a researcher at UPMC Hillman Cancer Center. “This opens the door to new therapies to improve the effectiveness of cancer immunotherapies.”
Her colleague, Greg Delgoffe, a professor in the same department, admitted the team did not expect to find such a direct connection. “What we found was remarkable,” he said. “Whether we damaged the mitochondria or the telomeres, we got the same result: dysfunctional T cells. There is crosstalk between the engine of the cell and the brains of the cell, the mitochondria and the nucleus. This is something we didn’t necessarily appreciate, at least in the immune system.”
The project began as a study of mitochondria and how their stress affects T cells. But with the help of Patricia Opresko, professor of pharmacology and chemical biology at Pitt, and the late Marcel Bruchez of Carnegie Mellon University, the research expanded to telomeres.
To test their ideas, the team engineered mice whose cells could create local oxidative damage when exposed to far-red light. The results were striking, whether the damage started at the mitochondria or at the telomeres, the outcome was the same exhausted T cells.
“When you damage the mitochondria, one of the first things that gets damaged is the telomeres,” Rivadeneira said. “And likewise, when you damage the telomeres, they talk back to the mitochondria to initiate a program that tells the cell to shut down and become exhausted.”
Once the researchers knew ROS were the culprits, they decided to try a direct antioxidant strategy. By tethering an antioxidant protein to the telomere region of mouse T cells, they were able to neutralize the harmful molecules exactly where the damage happens. When these engineered T cells were injected into mice with melanoma, the results were clear: the tumors were smaller and survival improved compared to animals treated with normal T cells.
The study’s biggest promise may lie in its application to CAR-T therapy, a treatment where doctors take a patient’s T cells, engineer them to recognize cancer cells, and put them back into the body. Right now, many CAR-T therapies lose effectiveness over time because the T cells grow tired. The new antioxidant method could give these cells extra endurance.
“This research is highly translatable because this approach could easily be incorporated into standard CAR-T protocol,” said Delgoffe. “While you’re genetically engineering T cells to improve cancer-fighting capability, you could also make them bulletproof against oxidative damage.”
The next step is to adapt the technique for human T cells. The Pitt team is already working on this goal, with plans to prepare for clinical trials in the future. Rivadeneira has also launched a new lab where she hopes to study how telomere health affects the immune system more broadly. One of her interests is understanding how chemotherapy, which is known to damage DNA, might influence T cell function and a patient’s response to immunotherapy.
Cancer immunotherapy has already given patients hope where little existed before, but a major problem has remained: the immune system’s soldiers often collapse before they can finish the battle. This new study shows a way to keep them strong for longer.
“This is only the beginning,” Rivadeneira said. “If we can protect telomeres, we may be able to give patients a stronger immune system and better chances against cancer.”
